First in Class Biologic to Enter Rheumatoid Arthritis Fray  

Oleh:

Garber, Ken ; Arbor, Ann

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 11 (Nov. 2005), page 1323-1324.
Topik: ARTHRITIS; biologic; rheumatoid arthritis fray

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.4 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

A completely novel biologic for the treament of rheumatoid arthristis (RA) us poised to enter the US market following a september US food and drug administration (FDA) committee approval recommendation for bristol myers squibb's fusion protein orencia (abatacept). Other novel trearments will soon follow, challenging the dominance of tumor necrosis factor (TNF) clockers, such as centocor's remicade (infliximab), angen / wyeth's enbrel (etanercept) and abbott's humira (adalimunab). Meanwhile pipeline attrition also contines unabated, with regeneron's interleukin- 1 trap molecule the latest casualty in the highly crowded and competitive field.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali